Bayer begins $240m AI drug discovery project with Exscientia

10-01-2020

Sarah Morgan

Bayer begins $240m AI drug discovery project with Exscientia

Thomas Quack / Shutterstock.com

Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.


Bayer, Exscientia, artificial intelligence, drug discovery, collaboration, cardiovascular, oncology, technology

LSIPR